Key Highlights

  • Geron Corporation (NASDAQ:GERN) reported Q2 2026 net revenue of $57.5 million, beating the $55.3 million estimate by 3.94 percent.
  • Rytelo net revenue grew 17 percent year over year and 11 percent quarter over quarter to $57.5 million.
  • The company reaffirmed full fiscal 2026 Rytelo net revenue guidance of $220 million to $240 million.
  • Cash, cash equivalents, and marketable securities totaled approximately $327 million as of June 30.

Rytelo Sales Growth Beats Estimates as Prescriber Base Expands

Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company headquartered in Foster City, California, focused on the treatment of myeloid hematologic malignancies through telomerase inhibition, reported second quarter net revenue growth of 17 percent year over year and 11 percent quarter over quarter to $57.5 million, with first half 2026 revenue growing approximately 24 percent versus the same period in 2025 and total operating expenses decreased 4 percent year over year for H1.

Adjusted EPS of negative $0.02 compared with an estimated negative $0.01, representing a miss of 100 percent on a percentage basis, though revenue of $57.5 million topped the $55.3 million estimate by 3.94 percent. Commercially, Rytelo achieved 5 percent demand growth quarter over quarter, an 8 percent increase in prescribing accounts since launch, and 34 percent first and second line market share within a rolling 12 month basis; the company estimates about 8,000 eligible second line lower-risk MDS patients in the US and plans to share European commercialization plans by year end.

Full-Year Guidance Reaffirmed as Pivotal Myelofibrosis Study Advances

The company expects to come in at the mid to high end of full year 2026 Rytelo net product revenue guidance range of $220 million to $240 million, and reaffirmed full year operating expense guidance of $230 million to $240 million for 2026; gross net deductions expected in the low to mid 20s for remainder of 2026. Cash, cash equivalents, restricted cash, and marketable securities were approximately $327 million as of June 30, 2026, down from $341 million as of March 31, 2026, with the company believing it has sufficient resources to fund current operations and growth.

For the Phase 3 Impact MF trial studying imetelstat in myelofibrosis, the company is considering a modification to the event threshold for the interim analysis after regulators asked questions, but projected timelines remain unchanged, with base case interim progression for final overall survival analysis in the second half of 2027; an earlier progression outcome would be an upside scenario. The Phase 3 Impact study represents a key pipeline catalyst beyond Rytelo's current MDS indication, with a positive outcome potentially expanding Geron's addressable market into myelofibrosis, a related hematologic malignancy.

Balancing Growing Commercial Traction Against Continued Cash Burn

Rytelo's continued quarter-over-quarter demand growth, expanding prescriber base, and strong market share within its first and second line indication suggest the drug's commercial launch continues to gain traction, supporting management's confidence in reaching the mid to high end of full-year revenue guidance. Should this trajectory continue, along with planned European commercialization details expected by year end, Geron's revenue base could see further diversification beyond the US market.

However, the company's cash position declined from $341 million to $327 million during the quarter, and continued operating expenses in the $230 million to $240 million range for the full year mean Geron will need sustained revenue growth to manage its cash runway, even as management expressed confidence in having sufficient resources to fund current operations and growth. The outcome of the Phase 3 Impact MF study, with its interim analysis potentially arriving as early as an upside scenario before the base case second half of 2027 timeline, represents a significant catalyst that could meaningfully affect the company's long-term trajectory.

Conclusion

Geron's second quarter results reflect continued commercial momentum for Rytelo, with revenue beating estimates and full-year guidance reaffirmed toward the higher end of the company's range. Whether Geron can sustain this growth trajectory while managing its cash position may depend on continued prescriber base expansion and the eventual outcome of its pivotal Phase 3 Impact study in myelofibrosis. The potential for European commercialization details by year end adds a further growth avenue beyond the current US-focused Rytelo launch.